Total Funding
73
62
Total FundingPost-IPO Equity raised
Growth Score
-15 pts
Heat Score
-2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
47020
Evaxion is a biotechnology company that specializes in the vaccine and immunotherapy development through artificial intelligence.
- Jens Kringelum: Director, Genomic Immuno Oncology
- Andreas Holm Mattsson: Chief Innovation Officer and FounderPast Role: Evaxion, Founder and CSO
About the Company
Evaxion is an AI-driven biotech company that uses its proprietary AI-Immunology™ platform to identify vaccine targets across cancer and infectious diseases. Its clinical programs include a personalized cancer vaccine in Phase II, and preclinical candidates targeting Staphylococcus aureus, gonorrhea, CMV, and more.
